Compare · ACON vs ILMN
ACON vs ILMN
Side-by-side comparison of Aclarion Inc. (ACON) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACON and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $33.97B, about 4733.6x ACON ($7.2M).
- ILMN has been more active in the news (11 items in the past 4 weeks vs 10 for ACON).
- ILMN has more recent analyst coverage (25 ratings vs 0 for ACON).
- Company
- Aclarion Inc.
- Illumina Inc.
- Price
- $2.46-7.87%
- $225.01+0.76%
- Market cap
- $7.2M
- $33.97B
- 1M return
- -
- +18.79%
- 1Y return
- -
- +127.94%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2000
- News (4w)
- 10
- 11
- Recent ratings
- 0
- 25
Aclarion Inc.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ACON
- Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
- Director Williams Amanda M bought $15,990 worth of shares (5,857 units at $2.73), increasing direct ownership by 29% to 25,857 units (SEC Form 4)
- CFO Gould Gregory A bought $24,500 worth of shares (10,000 units at $2.45), increasing direct ownership by 20% to 60,000 units (SEC Form 4)
- Chief Executive Officer Ness Brent bought $12,091 worth of shares (5,234 units at $2.31), increasing direct ownership by 5% to 111,534 units (SEC Form 4)
- Director Bond Ryan bought $50,059 worth of shares (21,122 units at $2.37), increasing direct ownership by 38% to 76,122 units (SEC Form 4)
- Director Wesemann William bought $5,031 worth of shares (2,150 units at $2.34), increasing direct ownership by 10% to 23,713 units (SEC Form 4)
- Director Neal David K bought $18,000 worth of shares (7,500 units at $2.40), increasing direct ownership by 33% to 30,002 units (SEC Form 4)
- Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
- SEC Form 10-Q filed by Aclarion Inc.
- Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
Latest ILMN
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)